Nemaura touts data from home-use study of wearable glucose monitor

This article was originally published here

Nemaura Medical (NSDQ:NMRD) said today that it launched a study of its wearable glucose monitor in the hopes of winning regulatory approval in the U.S.

The England-based company touted positive interim data from the study, focusing on the at-home use of the sugarBeat device.

Get the full story at our sister site, Drug Delivery Business News.

The post Nemaura touts data from home-use study of wearable glucose monitor appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply